A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients

BACKGROUND: Up to 30% of breast cancer (BC) patients treated with neoadjuvant chemotherapy (NCT) will relapse. Our objective was to analyze the predictive capacity of several markers associated with immune response and cell proliferation combined with clinical parameters. METHODS: This was a single-...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Torralba, Esmeralda, Navarro Manzano, Esther, Luengo-Gil, Gines, De la Morena Barrio, Pilar, Chaves Benito, Asunción, Pérez-Ramos, Miguel, Álvarez-Abril, Beatriz, Ivars Rubio, Alejandra, García-Garre, Elisa, Ayala de la Peña, Francisco, García-Martínez, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258327/
https://www.ncbi.nlm.nih.gov/pubmed/37313470
http://dx.doi.org/10.3389/fonc.2023.1182725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258327/
https://www.ncbi.nlm.nih.gov/pubmed/37313470
http://dx.doi.org/10.3389/fonc.2023.1182725

Ejemplares similares